• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

The CREOLE trial: amlodipine and either hydrochlorothiazide or perindopril optimally lowers blood pressure in black African patients

byDayton McMillan
June 23, 2019
in Cardiology, Chronic Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Black African patients with hypertension randomized to multiple two-drug combinations experienced greater blood pressure control when treated with amlodipine plus either hydrochlorothiazide or perindopril compared to those treated with perindopril plus hydrochlorothiazide.

2. Adverse event rates were similar in all three treatment groups.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Hypertension is the most notable contributor to global disease burden, and blood pressure control can notably reduce morbidity and mortality. To reach blood pressures of less than 140/90 mmHg, duel therapy is often needed. Hypertensive therapies recommended for black African patients differ in the United States and Europe, thus more definitive studies comparing therapeutic options are needed. The Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (CREOLE) trial evaluated various combinations of a calcium-channel blocker (amlodipine), thiazide diuretic (hydrochlorothiazide), and angiotensin-converting–enzyme (ACE) inhibitor (perindopril). The primary end-point of change in 24-hour systolic blood pressure between baseline and after 6 months of treatment showed the use of amlodipine plus either hydrochlorothiazide or perindopril were similarly effective, and more effective than perindopril plus hydrochlorothiazide.

Strengths of the study include its use of 24-hour blood pressure monitoring and evaluation of multiple two-drug therapies, while the study is limited by its lack of statistical adjustment for multiple comparison testing.

Click to read the study in NEJM

Relevant Reading: Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa

RELATED REPORTS

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

Dietary insoluble fiber intake may be associated with lower risk of hypertension

In-Depth [randomized controlled trial]: This randomized controlled trial enrolled patients between June and December 2017 in 6 sub-Saharan African countries. Eligible patients were black, between the ages of 30 and 79, had not received prior hypertensive treatment and had a systolic blood pressure of between 150 and 179 mmHg when seated at an office visit, or when on monotherapy and had a systolic blood pressure of between 140 and 159 mmHg. Patients who were pregnant or with a history of secondary hypertension or cardiovascular disease were excluded from the study. At baseline and after 6 months of treatment, patients had 24-hour blood pressures taken. Randomization into three groups was done in a 1:1:1 manner: 5mg amlodipine plus 12.5mg hydrochlorothiazide daily (n=216), 5mg amlodipine plus 4mg perindopril daily (n=205), or 4mg perindopril plus 12.5mg hydrochlorothiazide daily (n=200). After 2 months, doses were doubled unless patients had unacceptable side effects. The primary end point of mean change in systolic blood pressure between baseline and 6 months was −3.14 mmHg (95% confidence interval [CI], −5.90 to −0.38; P=0.03) for the amlodipine/hydrochlorothiazide group compared to the perindopril/hydrochlorothiazide group. For the amlodipine/perindopril group, the mean change was −3.00 mmHg (95% CI, −5.81 to −0.20 mm Hg; P = 0.04) compared to the perindopril/hydrochlorothiazide group. Reductions in office measured systolic blood pressures were greater in patients receiving amlodipine as well, and the difference was greater than in the 24-hour measurements. Adherence to treatment medications was similar in all three groups, and rates of adverse effects were also similar in all three groups.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: ACE inhibitorsamlodipineblood pressurecalcium channel blocker (CCB)hydrochlorothiazidehypertensionperindoprilthiazide diuretic
Previous Post

#VisualAbstract: Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

Next Post

Quick Take: HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception

RelatedReports

UTI associated with increased risk of preeclampsia
Cardiology

Ultrasound renal denervation associated with reduced blood pressure in the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials – A pooled analysis

March 6, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Endovascular ultrasound renal denervation associated with lower ambulatory systolic blood pressure in patients with hypertension – The RADIANCE II randomized clinical trial

March 6, 2023
Provision of medically-tailored meals linked with lower admissions and medical spending
Cardiology

Dietary insoluble fiber intake may be associated with lower risk of hypertension

February 22, 2023
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Telephone health coaching intervention ineffective for improving outcomes for hypertension

February 11, 2023
Next Post
Government-funded initiatives provide important supports to low-income HIV patients

Quick Take: HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

Quick Take: Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Evobrutinib reduces imaging findings of multiple sclerosis but not clinical progression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Similar perinatal outcomes observed amongst conception via natural and assisted reproductive means
  • Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus
  • Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options